Form 603

Corporations Act 2001 Section 671B

Notice of initial substantial holder

| To_ Company Name/Scheme | Cyclopharm Limited |
|--------------------------------|--|
| ACN/ARSN | 116 931 250 |
| 1. Details of substantial hold | ler (1) Karst Peak Capital Limited and the persons detailed in Annexure A |
| ACN/ARSN (if applicable) | n/a |
| | |

The holder became a substantial holder on

24/12/2019

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

| Class of securities (4) | Number of securities | Person's votes (5) | Voting power (6) |
|-------------------------|----------------------|--------------------|------------------|
| See Annexure A | | | |
| | | | |

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

| Holder of relevant interest | Nature of relevant interest (7) | Class and number of securities |
|-----------------------------|---------------------------------|--------------------------------|
| See Annexure A | | · |
| | | |

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

| Holder of relevant interest | Registered holder of securities | Person entitled to be registered as holder (8) | Class and number of securities |
|-----------------------------|---------------------------------|--|--------------------------------|
| See Annexure A | | | |
| | | | |

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

| Holder of relevant interest | Date of acquisition | Considerati | on (9) | Class and number of securities |
|-----------------------------|---------------------|-------------|----------|--------------------------------|
| See Annexure A | | Cash | Non-cash | |
| | | | | |
| | | | | |

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

| Name and ACN/ARSN (if applicable) | Nature of association | |
|-----------------------------------|-----------------------|--|
| See Annexure A | | |
| | | |

7. Addresses

The addresses of persons named in this form are as follows:

| Name | Address |
|----------------|---------|
| See Annexure A | |
| | |

Signature

print name Ivan Goh

capacity Authorised Signatory

sign here

date 30 / 12 / 2019

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (cg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of
 - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

Annexure A

This is Annexure A of 2 pages referred to in the Form 603 for Cyclopharm Limited ("CYC").

2. Previous and present voting power:

| Notice Giver | Class of Securities | Person's votes | Voting power |
|--|------------------------------------|----------------|--------------|
| Karst Peak Asia Master Fund ("KPAMF") | Fully Paid Ordinary Shares ("FPO") | 4,665,650 | 6.69% |
| Vermilion Peak Master Fund ("VPMF") | FPO | 3,834,350 | 5.50% |
| Karst Peak Capital Limited ("KPCL") | FPO | 8,500,000 | 12.19% |
| Adam Gregory Leitzes ("AGL") | FPO | 8,500,000 | 12.19% |

3. Details of relevant interests:

| Holder of relevant interest | Nature of relevant interest | Class and number of securities |
|-----------------------------|---|--------------------------------|
| KPAMF | Owner of FPO | 4,665,650 FPO |
| VPMF | Owner of FPO | 3,834,350 FPO |
| KPCL | Discretionary investment manager to KPAMF and VPMF. | 8,500,000 FPO |
| AGL | Shareholder, Director and Chief Investment Officer of KPCL, as well as a Director of KPAMF and VPMF | 8,500,000 FPO |

Details of present registered holders:

| Holder of relevant interest | Registered holder of securities | Person entitled to be registered as holder | Class and number of securities |
|-----------------------------|---|--|--------------------------------|
| KPCL, AGL and KPAMF | HSBC Bank Australia Limited ("HSBC") | HSBC | 4,665,650 FPO |
| KPCL, AGL and VPMF | HSBC | HSBC | 3,834,350 FPO |

5. Changes in association:

No changes in associates nor nature of their association.

6. Addresses:

| Name | Address |
|-------|--|
| KPAMF | c/o Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman |
| | Islands |
| VPMF | c/o Maples Corporate Services Limited, PO Box 309, |
| | Ugland House, Grand Cayman, KY1-1104, Cayman |
| | Islands |

| KPCL | Suite 1705 Kinwick Centre, 32 Hollywood Road, | |
|------|---|--|
| | Central, Hong Kong | |
| AGL | Suite 1705 Kinwick Centre, 32 Hollywood Road, | |
| | Central, Hong Kong | |
| HSBC | GPO BOX 5302, Sydney NWS 2001, Australia | |

Signed

Ivan Goh, Authorised Signatory

30 December 2019